 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Review, Journal: Advances in Dystrophinopathy Diagnosis and Therapy. (Pubmed Central) - Oct 4, 2023
Other antisense oligonucleotide drugs in the pipeline include casimersen for exon 45, suvodirsen for exon 51, and golodirsen for exon 53 skipping. Advances in the diagnosis and therapy of dystrophinopathies offer new perspectives for their early discovery and care.
- suvodirsen (WVE-210201) / Wave Life Sciences
Trial termination: DYSTANCE 51: Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Jan 18, 2020
P2/3, N=6, Terminated, Sponsor: Wave Life Sciences Ltd.
Advances in the diagnosis and therapy of dystrophinopathies offer new perspectives for their early discovery and care. Suspended --> Terminated; Lack of efficacy
- || suvodirsen (WVE-210201) / Wave Life Sciences
Enrollment change, Trial completion date, Trial suspension, Trial primary completion date: DYSTANCE 51: Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Dec 20, 2019
P2/3, N=6, Suspended, Sponsor: Wave Life Sciences Ltd.
Suspended --> Terminated; Lack of efficacy N=150 --> 6 | Trial completion date: Dec 2022 --> Mar 2020 | Recruiting --> Suspended | Trial primary completion date: Dec 2021 --> Dec 2019
- | suvodirsen (WVE-210201) / Wave Life Sciences
Enrollment open, Trial completion date, Trial primary completion date: DYSTANCE 51: Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Oct 7, 2019
P2/3, N=150, Recruiting, Sponsor: Wave Life Sciences Ltd.
N=150 --> 6 | Trial completion date: Dec 2022 --> Mar 2020 | Recruiting --> Suspended | Trial primary completion date: Dec 2021 --> Dec 2019 Not yet recruiting --> Recruiting | Trial completion date: Aug 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Dec 2021
- |||||||| suvodirsen (WVE-210201) / Wave Life Sciences
New P2/3 trial: DYSTANCE 51: Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Apr 8, 2019
P2/3, N=150, Not yet recruiting, Sponsor: Wave Life Sciences Ltd.
- || suvodirsen (WVE-210201) / Wave Life Sciences
Trial completion: Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Apr 8, 2019
P1, N=36, Completed, Sponsor: Wave Life Sciences Ltd.
Not yet recruiting --> Recruiting | Trial completion date: Aug 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Dec 2021 Active, not recruiting --> Completed
- || suvodirsen (WVE-210201) / Wave Life Sciences
Enrollment closed: Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Jan 7, 2019
P1, N=40, Active, not recruiting, Sponsor: Wave Life Sciences Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | suvodirsen (WVE-210201) / Wave Life Sciences
Trial completion date, Trial primary completion date: Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Oct 17, 2018
P1, N=40, Recruiting, Sponsor: Wave Life Sciences Ltd.
Recruiting --> Active, not recruiting Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019
- || suvodirsen (WVE-210201) / Wave Life Sciences
New P1 trial: A Study of WVE-210201 in Patients Previously Enrolled in WVE-DMDX51-001 (EUDRACT) - Sep 4, 2018
P1, N=40, , Sponsor: Wave Life Sciences Ltd.
- | suvodirsen (WVE-210201) / Wave Life Sciences
New P1 trial: Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Apr 25, 2018
P1, N=40, Recruiting, Sponsor: Wave Life Sciences Ltd.